Dechra Pharmaceuticals plc (DPH.L)


LSE - LSE Delayed Price. Currency in GBp
1,393.00+15.00 (+1.09%)
At close: 12:15 PM EDT
People also watch:
DTY.LDPLM.LGNS.LCWK.LHIK.L
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1,359.00
Prev Close1,378.00
Bid1,300.00 x 34700
Ask0.00 x 29800
Day's Range1,359.00 - 1,395.00
52wk Range811.00 - 1,423.00
1y Target EstN/A
Market Cap1.29B
P/E Ratio (ttm)98.79
BetaN/A
Volume324,232
Avg Vol (3m)126,235
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Dechra Pharmaceuticals Plc : Overvalued relative to peers, but may deserve another look
    Capital Cube3 days ago

    Dechra Pharmaceuticals Plc : Overvalued relative to peers, but may deserve another look

    Categories: Yahoo Finance Dechra Pharmaceuticals Plc relative valuation is now OVERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 53. Our analysis is based on comparing Dechra Pharmaceuticals Plc with the following peers – Alliance Pharma plc, Hikma Pharmaceuticals Plc, Vectura Group plc, ECO Animal Health Group plc, BTG plc, GlaxoSmithKline plc, Sinclair Pharma ... Read more (Read more...)

  • Dechra Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : DPH-GB : September 26, 2016
    Capital Cube6 days ago

    Dechra Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : DPH-GB : September 26, 2016

    Categories: Europe Stock Alerts Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Dechra Pharmaceuticals Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • PR Newswire16 days ago

    Proposed Acquisition of Apex Laboratories Pty Ltd

    Dechra Pharmaceuticals PLC (Stock Code: Full Listing (Pharmaceuticals): DPH) is pleased to announce that it has agreed terms to acquire the business and assets of Apex Laboratories Pty Ltd ('Apex'), a privately owned veterinary pharmaceutical company which manufactures, markets and sells branded non-proprietary prescription and other related companion animal products in Australia and New Zealand (the 'Acquisition'). The Acquisition includes the purchase of Apex's manufacturing site. Apex is ultimately controlled by Mr Anthony McGloin who is a descendant of the founder of Apex.